To evaluate the effect of RAC1A159V mutation on tumor cells, we used CRISPR-Cas9–mediated knock-in technology to introduce the A159V mutation to the endogenous RAC1 locus of the MC38 colon cancer cells (Fig. 1A). Here, RAC1 is linked to neoplasm.